ANTIHYPERLIPIDEMIC EFFECT OF KOMOOTHIRA SILASATHU PARPAM IN TRITON-INDUCED ANTI DYSLIPIDEMIC RATS

Revathy P, Thirunarayanan G, Suvedha P

Abstract

Background: Cardiovascular disease (CVD) is known to be associated with hyperlipidemia. The statin medicine class inhibits a stage that limits the production of cholesterol at a certain pace, although all statins have negative effects on the musculoskeletal system. The current interest has led to a hunt for novel lipid-lowering drugs with little to no side effects among traditional sources of siddha. Objective: The primary goal of this study is to assess the siddha formulation Komoothira silasathu parpam (KSP)’s antityperlipidemic capability in triton-induced dyslipidemic rats. Methods: Triton was used for the induction of hyperlipidemia in the experimental animals. The animals were divided into control, disease control and treatment groups. Rats belongs to treatment groups were administered test drug KSP at doses of 250 and 500 mg/kg/p.o. Results: The data of the present investigation clearly emphasise that the body weight, total cholesterol, HDL, LDL, VLDL, and triglyceride levels of the triton group demonstrate a significant increase in comparison with normal control rats. Treatment with the siddha formulation KSP at 250 and 500 mg/kg doses results in a significant decrease in the total lipid profile and body weight of the experimental animals, Furthermore, the KSP treatment causes a Consistent decrease in the internal organ weight (heart and liver) of the animals. Histological examination of the liver sample confirms the existence of inflammatory changes in triton treatment, and treatment with PVC reveals a restorative nature in both the dose level. Conclusion: In conclusion, the data of the present study show that the siddha formulation KSP reveals promising antihyperlipidemic activity in Triton induced dyslipidemic rats. Hence KSP type formulations may be the good drug of choice in the clinical management of hyperlipidemia

Keywords: Hyperlipidemia, Siddha, Komoothira silasathu parpam, Lipid profile, Body weight, Histopathology.

Full Text:

PDF

References

Smith Jr SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006, update: endorsed by the National Heart, Lung, and Blood Institute. Circulation, 113(19):2363-72.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25):e1046-81.

Joy TR, Hegele RA. (2009), Narrative review: statin-related myopathy. Annals of Internal Medicine, 16;150(12):858-68.

Kumar MS, Kirubanandan S, et. al. (2008), Hypolipidemic and antioxidant effects of Siddha polyherbal formulation Sindoora Chendhuram: A preclinical study. J Ethnopharmacol, 211:178-185.

Meena, MS, et al. (2010), Pharmacognostical Studies on Siddha Drug-Kadukkai (Terminalia chebula Retz). Journal of Pharmaceutical Research, 9(3), 135-138.

Pal SK, Shukla Y. (2003), Herbal medicine: current status and the future. Asian pacific Journal of Cancer Prevention, 4(4):281-8.

Ramos R, Comas-Cufí M, Martí-Lluch R, Balló E, Ponjoan A, Alves-Cabratosa L, Blanch J, Marrugat J, Elosua R, Grau M, Elosua-Bayes M. (2018), Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ, 5;362.

Ference BA, Kastelein JJ, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS (2017), Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. Jama, 318(10):947-56.

Brown MS, Goldstein JL. (1986), A receptor-mediated pathway for cholesterol homeostasis. Science, 232(4746):34-47.

Mollace V, Sacco I, Janda E, Malara C, Ventrice D, Colica C, Visalli V, Muscoli S, Ragusa S, Muscoli C, Rotiroti D. (2011), Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia, 82(3):309-16.

Trimarco V, Cimmino CS, Santoro M, Pagnano G, Manzi MV, Piglia A, Giudice CA, De Luca N, Izzo R. (2012) Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension. High Blood Pressure & Cardiovascular Prevention, 19:117-22.

Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T. (2010), NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 464(7293):1357-61.

Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH (2009), The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. Journal of Lipid Research, 50:S189-94.

Repa JJ, Turley SD, Lobaccaro JM, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ (2000), Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science, 289(5484):1524-9.

Nicholls SJ, Puri R, Wolski K, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Hu B, Uno K, Kataoka Y, Herrman JP (2016), Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. American Journal of Cardiovascular Drugs, 16:55-65.

Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977), High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. The American Journal of Medicine, 62(5):707-14.

Hariri N, Thibault L. (2010), High-fat diet-induced obesity in animal models. Nutrition Research Reviews, 23(2):270-99.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P (2011), Triglyceride-rich lipoproteins and high-

density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. European Heart Journal, 32(11):1345-61.

Kumar G, Srivastava A, Sharma SK, Gupta YK (2013), The hypolipidemic activity of ayurvedic medicine, arogyavardhini vati in triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate. Journal of Ayurveda and Integrative Medicine, 4(3):165.

Raja NN, Ranganathan S, Natarajan A. (2023), Antihyperlipidemic potential of siddha formulation-pavala veera chunnam in high fat diet induced hyperlipidemic rats, HIV Nursing, 23(3):347-52.

Kuriyan R, Raj T, Srinivas SK, Vaz M, Rajendran R, Kurpad AV. (2007), Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. Appetite, 48(3):338-44.

Goldberg IJ, Eckel RH, McPherson R (2011), Triglycerides and heart disease: Still a hypothesis? Arteriosclerosis. Thrombosis, and Vascular Biology, 31(8):1716-25.

Refbacks

  • There are currently no refbacks.


Bookmark and Share